Immunocore

Read more
Bahija Jallal's photo - CEO of Immunocore

CEO

Bahija Jallal

CEO Approval Rating

90/100

Founded:

2008

Status:

PublicIndependent CompanyNASDAQIMCR

Annual Revenue
$40.9M
Employees
291

IMMUNOCORE TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Immunocore's company profile
Bahija Jallal's photo - CEO of Immunocore

Bahija Jallal

CEO

90/100
291
$923.3M
$40.9M
View Profile
1
Immunocore's Competitor - Gritstone Oncology logo
Andrew Allen's photo - President & CEO of Gritstone Oncology

Andrew Allen

President & CEO

90/100
113
$419.7M
$44.8M
View Profile
2
Immunocore's Competitor - Adaptimmune logo
Adrian Rawcliffe's photo - CEO of Adaptimmune

Adrian Rawcliffe

CEO

91/100
462
$358.7M
$6.2M
View Profile
3
Immunocore's Competitor - Regeneron logo
Leonard S Schleifer's photo - President & CEO of Regeneron

Leonard S Schleifer

President & CEO

78/100
7,400
$2.1B
$12.4B
View Profile
4
Immunocore's Competitor - Medigene logo
Dolores J. Schendel's photo - CEO of Medigene

Dolores J. Schendel

CEO

68/100
142
$251.2M
$9.7M
View Profile
5
Immunocore's Competitor - Gilead logo
Daniel O’Day's photo - Chairman & CEO of Gilead

Daniel O’Day

Chairman & CEO

66/100
11,000
$7.3B
$26.6B
View Profile
6
Immunocore's Competitor - Allogene logo
David Chang's photo - President & CEO of Allogene

David Chang

President & CEO

93/100
122
$819.8M
$153.4M
View Profile
7
Immunocore's Competitor - Kuur Therapeutics logo
Kevin S. Boyle's photo - CEO of Kuur Therapeutics

Kevin S. Boyle

CEO

90/100
51
$194.5M
$3.2M
View Profile
8
Immunocore's Competitor - Tmunity logo
Usman Oz Azam's photo - President & CEO of Tmunity

Usman Oz Azam

President & CEO

90/100
70
$230M
$5M
View Profile
9
Immunocore's Competitor - bluebird bio logo
Nick Leschly's photo - President & CEO of bluebird bio

Nick Leschly

President & CEO

74/100
764
$526.4M
$50.2M
View Profile
10
Immunocore's Competitor - Adimab logo
Tillman U. Gerngross's photo - Co-Founder & CEO of Adimab

Tillman U. Gerngross

Co-Founder & CEO

90/100
121
$32.3M
$15M
View Profile
11
Immunocore's Competitor - Kite Pharma logo
Christi L. Shaw's photo - CEO of Kite Pharma

Christi L. Shaw

CEO

81/100
2,000
$634.9M
$45M
View Profile
12
Immunocore's Competitor - NexImmune logo
Scott P. Carmer's photo - CEO of NexImmune

Scott P. Carmer

CEO

85/100
44
$162.8M
View Profile

Missing a competitor? Contribute!

Gritstone Oncology is a top competitor of Immunocore. Gritstone Oncology was founded in 2015, and is headquartered in Emeryville, California. Like Immunocore, Gritstone Oncology also competes in the Biotechnology field. Gritstone Oncology generates $3.9M more revenue vs. Immunocore.

Adaptimmune is seen as one of Immunocore's top competitors. Adaptimmune is headquartered in Oxfordshire, England, and was founded in 2008. Like Immunocore, Adaptimmune also operates in the Biotechnology field. Adaptimmune generates 15% the revenue of Immunocore.

Regeneron has been one of Immunocore's top competitors. Regeneron's headquarters is in Tarrytown, New York, and was founded in 1988. Like Immunocore, Regeneron also works within the Biotechnology industry. Regeneron generates 22,495% of Immunocore's revenue.

Immunocore Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$40.9M

Immunocore's revenue is the ranked 9th among it's top 10 competitors. The top 10 competitors average 5B. Over the last two quarters, Immunocore's revenue has decreased by 0%. Specifically, in Q4 2020's revenue was $40.9M; in Q3 2020, it was $40.9M.

Immunocore Acquisitions

No recent acquisitions found related to Immunocore

Immunocore Funding History

Since Immunocore was founded in 2008, it has participated in 6 rounds of funding. In total Immunocore has raised $923.3M. Immunocore's last funding round was on Feb 2021 for a total of $258.3M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Feb 2021
$258.3M
-
Series C
Jan 2021
$75M
Debt
Jan 2021
$100M
Series B
Feb 2020
$130M
Equity
Sep 2017
$40M

Since Immunocore was founded in 2008, it has participated in 6 rounds of funding. In total Immunocore has raised $923.3M. Immunocore's last funding round was on Feb 2021 for a total of $258.3M

Immunocore Investments

No recent investments found related to Immunocore

Immunocore News

August 11, 2021BioSpace

Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update

Immunocore Holdings plc, a late-stage biotechnology company pioneering the development of a novel cla... See more »
May 27, 2021Markets Insider

Immunocore to present at upcoming investor conferences

PRESS RELEASE Immunocoreto present at upcoming investor conferences(OXFORDSHIRE, England & CONSHOHOCK... See more »
May 18, 2021MarketScreener

Immunocore announces dosing of first patient with ImmTAV bispecific molecule for chronic Hepatitis B

(marketscreener.com) PRESS RELEASE Immunocore announces dosing of first patient with ImmTAV® bispecif... See more »
May 12, 2021BioSpace

Immunocore Reports First Quarter 2021 Financial Results

Immunocore today announced its results for the quarter ended March 31, 2021.... See more »

Immunocore Press Releases

March 25, 2021GlobeNewswire

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results... See more »
June 4, 2018Business Wire

New IMCgp100-102 Data Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma

OXFORD, England & CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Patients with metastatic uveal melanoma (mUM) t... See more »
January 4, 2018EconoTimes

Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors

Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-E... See more »
December 8, 2015Business Wire

Uveal Melanoma - Pipeline Review, Technologies & Forecasts Report H2 2015

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xssp56/uvea... See more »

Immunocore Videos

April 4, 2016Immunocore Youtube Channel

"ImmTACs in action" on YOUTUBE

April 4, 2016Immunocore Youtube Channel

"ImmTAC molecules in action" on YOUTUBE

Social Media

Immunocore Headquarters

92 Park Drive Milton Park , Abingdon

Oxfordshire, EnglandOX14 4RY

44-1235-438600

Driving Directions »

Trending Companies

Immunocore Summary

ABOUT

Overview

Immunocore is an England-based biotechnology company that develops and commercializes biological therapies for the treatment of cancer. Immunocore was founded in 2008. Immunocore's headquarters is located in Oxfordshire, England, GB OX14 4RY. It has r...

CEO

Immunocore's CEO, Bahija Jallal, currently has an approval rating of 90%. Immunocore's primary competitors are Gritstone Oncology, Adaptimmune & Regeneron.

Frequently Asked Questions about Immunocore

  1. When was Immunocore founded?

    Immunocore was founded in 2008
  2. Who is Immunocore's CEO?

    Immunocore's CEO is Bahija Jallal
  3. How much revenue does Immunocore generate?

    Immunocore generates $40.9M in revenue
  4. How much funding does Immunocore have?

    Immunocore has historically raised $923.3M in funding
  1. Where is Immunocore's headquarters?

    Immunocore's headquarters is in Oxfordshire England, GB
  2. How many employees does Immunocore have?

    Immunocore has 291 employees
  3. What sector does Immunocore operate in?

    Immunocore is in Biotechnology
  4. Who are Immunocore's competitors?

    Immunocore's top competitors are Gritstone Oncology, Adaptimmune, Regeneron